We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
In the latest close session, Boston Scientific (BSX - Free Report) was down 2.65% at $105.23. This move lagged the S&P 500's daily gain of 0.3%. Elsewhere, the Dow saw a downswing of 0.48%, while the tech-heavy Nasdaq appreciated by 0.03%.
Shares of the medical device manufacturer witnessed a gain of 5.31% over the previous month, trailing the performance of the Medical sector with its gain of 7.07%, and outperforming the S&P 500's gain of 2.09%.
Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on October 22, 2025. The company's earnings per share (EPS) are projected to be $0.71, reflecting a 12.7% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $4.95 billion, up 17.68% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.98 per share and a revenue of $19.84 billion, representing changes of +18.73% and +18.45%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Boston Scientific. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.01% lower. At present, Boston Scientific boasts a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Boston Scientific has a Forward P/E ratio of 36.32 right now. This represents a premium compared to its industry average Forward P/E of 19.01.
It's also important to note that BSX currently trades at a PEG ratio of 2.6. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 2.17.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 144, putting it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
In the latest close session, Boston Scientific (BSX - Free Report) was down 2.65% at $105.23. This move lagged the S&P 500's daily gain of 0.3%. Elsewhere, the Dow saw a downswing of 0.48%, while the tech-heavy Nasdaq appreciated by 0.03%.
Shares of the medical device manufacturer witnessed a gain of 5.31% over the previous month, trailing the performance of the Medical sector with its gain of 7.07%, and outperforming the S&P 500's gain of 2.09%.
Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on October 22, 2025. The company's earnings per share (EPS) are projected to be $0.71, reflecting a 12.7% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $4.95 billion, up 17.68% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.98 per share and a revenue of $19.84 billion, representing changes of +18.73% and +18.45%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Boston Scientific. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.01% lower. At present, Boston Scientific boasts a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Boston Scientific has a Forward P/E ratio of 36.32 right now. This represents a premium compared to its industry average Forward P/E of 19.01.
It's also important to note that BSX currently trades at a PEG ratio of 2.6. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 2.17.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 144, putting it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.